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Abstract 
Activating mutations and/or overexpression of fibroblast growth factor receptor 3 (FGFR3) are commonly 
observed in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. Recently 
FGFR3 gene rearrangements have been described that define a unique subset of bladder tumors. Here 
we show that the selective heat shock protein 90 (HSP90) inhibitor ganetespib induced loss of FGFR3-
TACC3 fusion protein expression and depletion of multiple oncogenic signaling proteins in RT112 bladder 
cells, resulting in potent cytotoxicity comparable to the pan-FGFR tyrosine kinase inhibitor BGJ398. In 
contrast to BGJ398, however, ganetespib exerted pleiotropic effects on additional mitogenic and survival 
pathways and could overcome the FGFR-inhibitor resistant phenotype of FGFR3 mutant-expressing 97-7 
and MHG-U3 cells. Combinatorial benefit was observed when ganetespib was used with BGJ398 both in 
vitro and in vivo. Interestingly, two additional FGFR3 fusion-positive lines (RT4 and SW480) retained 
sensitivity to HSP90 inhibitor treatment by the ansamycins 17-AAG and 17-DMAG yet displayed intrinsic 
resistance to ganetespib or AUY922, both second-generation resorcinol-based compounds. Both lines 
expressed considerably higher levels of endogenous UGT1A enzyme expression than RT112; this 
phenotype resulted in the rapid metabolism (via glucuronidation) and subsequent efflux of ganetespib 
from SW780 cells, thus providing a mechanism to account for the lack of bioactivity. 
Implications: These findings suggest that pharmacological blockade of the molecular chaperone HSP90 
represents a promising approach for treating bladder tumors driven by oncogenic gene rearrangements of 
FGFR3. Further, UDP-glucuronosyltransferase (UGT) enzyme expression may serve as a predictive 
factor for clinical response to resorcinol-based HSP90 inhibitors.  
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Introduction 
Bladder cancer represents the fifth most common malignancy worldwide and a major cause of cancer-
related morbidity and death. Incidence and mortality rates have remained relatively constant over the past 
four decades, with an estimated 72,570 new cases and 15,210 deaths predicted for 2013 in the U.S. 
alone (1). A vast majority of patients, over 70%, present with non-muscle invasive bladder cancer 
(NMIBC), previously referred to as ‘superficial’ bladder cancer (2). A proportion (around 10-20%) of these 
tumors may ultimately progress to invasive disease, but even the bulk percentage of these neoplasms 
have a characteristically high risk of recurrence which presents an immense challenge for the clinical 
management and ongoing surveillance of patients, often over many years. The remaining cases are 
diagnosed as muscle invasive bladder cancer (MIBC), a more aggressive stage of the disease that is 
associated with a higher risk of metastasis and for which the 5-year survival rates are only around 50% 
(2). Indeed, progression to metastatic bladder cancer, whether from recurrent NMIBC or MIBC, results in 
significantly poorer survival outcomes and is generally considered incurable (3). In contrast to other 
malignancies, advances in the management and treatment of bladder cancer have been limited (4); 
consequently there exists a considerable unmet need for novel therapeutic approaches to improve patient 
outcomes in this disease indication. 
Fibroblast growth factor receptor 3 (FGFR3) is a member of a structurally related family of tyrosine kinase 
receptors (FGFR1-4) that orchestrate a diverse variety of cellular activities, including proliferation, 
differentiation, and survival (5). Ligand binding promotes receptor dimerization, transphosphorylation of 
key tyrosine residues, and recruitment of adaptor proteins - ultimately leading to the activation of multiple 
downstream signaling cascades, including PI3K/AKT, RAS/MAPK, STATs, and phospholipase Cγ (PLCγ) 
(5). Somatic mutation of the FGFR3 gene is one of the most frequent genetic alterations seen in bladder 
cancer, occurring in around 75% of all cases of NMIBC (6, 7). Interestingly, most of the missense 
mutations identified in bladder tumors are identical to germline gain-of-function mutations responsible for 
autosomal dominant human skeletal disorders and dwarfism syndromes (5, 8). FGFR3 mutations are less 
prevalent in muscle-invasive tumors, which more commonly exhibit dysregulated FGFR3 function via 
overexpression of the wild-type protein (7). Recently, a third mechanism of aberrant FGFR3 activation in 
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bladder cancer has been identified that involves chromosomal rearrangements of FGFR3 with one of two 
different fusion partners: TACC3 (transforming acid coiled coil 3) or BAI1AP2L1 (BAI1-associated protein 
2-like 1) (9). Both FGFR3-TACC3 and FGFR3-BAI1AP2L1 translocations generate constitutively activated 
and oncogenic FGFR3 kinase protein products, and cellular dependence on these drivers confers 
sensitivity to selective FGFR inhibition (9, 10). In light of these and other considerations, FGFR3 has long 
been considered an attractive actionable target for novel therapeutic approaches in bladder cancer (11).  
The molecular chaperone heat shock protein 90 (HSP90) plays an essential role in regulating the 
maturation and functional stability of an extensive array of cellular client proteins, an activity that is often 
exploited by cancer cells to confer aberrant proliferative, survival, and/or metastatic potential (12, 13). 
Indeed the HSP90 machinery serves as a biochemical buffer for a number of oncogenic signaling 
proteins that have been causally implicated in a variety of human tumors; mutant oncoproteins have been 
shown to be particularly reliant on the chaperone (14, 15). Functional inhibition of HSP90 results in the 
simultaneous degradation of hundreds of clients; thus providing a mechanism to concomitantly disrupt 
multiple oncogenic signaling cascades through a singular molecular target. In this regard, 
pharmacological blockade of HSP90 has emerged as an innovative approach for the development of new 
antineoplastic agents (16).  
We have previously shown that selective targeting of HSP90 activity using ganetespib, a potent small 
molecule inhibitor of HSP90 (17), represents a valid and superior alternative approach to direct kinase 
inhibition in EML4-ALK fusion protein-driven lung cancer (18). Here we report on our evaluation of this 
strategy in FGFR3 fusion-positive bladder cancer cells. Ganetespib activity was examined in a panel of 
bladder lines to determine the comparative sensitivity of FGFR3-rearranged cells to this treatment 
modality. Additionally we explored the efficacy of combinatorial ganetespib plus FGFR inhibitor treatment 
as a means to optimize the antitumor potency of HSP90 blockade. Significantly, FGFR3 fusion-driven 
bladder cells showed differential sensitivity to alternate chemical classes of HSP90 inhibitors irrespective 
of the translocation present; and a series of studies were performed to dissect the underlying basis of this 
response. Overall, the results suggest that selective inhibition of HSP90 represents a new therapeutic 
opportunity to target bladder cancer cells driven by oncogenic rearrangements of FGFR3. Moreover, the 
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data identify additional molecular markers that may be indicative of intrinsic resistance to specific classes 
of small molecule HSP90 inhibitors, a finding with important translational implications for the potential 
clinical application of these drugs in bladder cancer. 
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Materials and Methods 
Cell lines, antibodies, and reagents  
The RT4 and SW780 cell lines were obtained from the American Type Culture Collection (ATCC). Each 
was maintained according to suppliers’ instructions, authenticated by routine company DNA typing, and 
used within six months of receipt. RT112 cells were obtained from Sigma-Aldrich. The 97-7 and MGH-U3 
lines are established in the Knowles laboratory and cell line identity was verified by short tandem repeat 
DNA typing using a Powerplex 16 kit (Promega). The remaining fifteen bladder lines listed in Table 1 are 
part of a collection assembled by the Center for Molecular Therapeutics (Massachusetts General Hospital 
Cancer Center) who performed the drug sensitivity analysis.  As part of the establishment of this cell line 
collection, a panel of 92 SNPs (single nucleotide polymorphisms) was profiled for each cell line and 
short tandem repeat analysis was also performed. All primary antibodies were purchased from Cell 
Signaling Technology with the exception of the FGFR3 (B9) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibodies (Santa Cruz Biotechnology, Inc.), UGT1A9 (Abcam), and UGT1A10 
(Novus Biologicals). Ganetespib [3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-1,2,4-triazol-5(4H)-
one] was synthesized by Synta Pharmaceuticals Corp. 17-AAG and 17-DMAG were purchased from LC 
Laboratories; BGJ398 and AUY922 from Selleck Chemicals; and propofol from Sigma Aldrich.  
Viability assays  
Cellular viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) 
according to manufacturer protocols. Bladder cancer cell lines were seeded into 96-well plates based on 
optimal growth rates determined empirically for each line. All viability assays were performed in triplicate. 
Twenty-four hours after plating, cells were dosed with graded concentrations of ganetespib for 72 hours. 
CellTiter-Glo was added (50% v/v) to the cells, and the plates incubated for 10 minutes prior to 
luminescent detection in a SpectraMax Plus 384 microplate reader (Molecular Devices).  Data were 
normalized to percent of control and IC50 values used to determine the sensitivity of each line. For the 
comparative analyses with ganetespib and BGJ398, RT112 cells were treated with graded concentrations 
of each compound for 72 hours and cell viability measured as above. For the evaluation of apoptotic 
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induction, caspase activity was assessed using the Caspase-Glo 3/7 assay (Promega) according to 
manufacturer protocols. Twenty-four hours after plating, RT112 cells were treated with graded 
concentrations of ganetespib for 24 hours. Caspase-Glo was added to cells (50% v/v) and the plates 
incubated for 1 hour prior to luminescent detection.  
Western blotting  
Following in vitro assays, tumor cells were disrupted in lysis buffer on ice for 10 minutes. Lysates were 
clarified by centrifugation and equal amounts of proteins resolved by SDS-PAGE before transfer to 
nitrocellulose membranes (Bio-Rad). Membranes were blocked with StartingBlock T20 blocking buffer 
(Thermo Scientific) and immunoblotted with the indicated antibodies. Antibody-antigen complexes were 
visualized using an Odyssey system (LI-COR).  
Reverse phase protein array  
RT112 cells were treated with dimethyl sulfoxide (DMSO, control) or 100 nM ganetespib for 24 hours. 
Lysates were prepared as recommended by MD Anderson Cancer Center (Houston, TX) with cellular 
proteins denatured by 1% SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial dilutions in 
dilution buffer (lysis buffer containing 1% SDS). Serial diluted lysates were arrayed on nitrocellulose-
coated slides (Grace Biolab) by an Aushon 2470 Arrayer (Aushon BioSystems). A total of 5808 array 
spots were arranged on each slide including the spots corresponding to positive and negative controls 
prepared from mixed cell lysates or dilution buffer, respectively. Each slide was probed with a validated 
primary antibody plus a biotin-conjugated secondary antibody (19). Only antibodies with a Pearson 
correlation coefficient between RPPA and western blotting of greater than 0.7 were used in reverse phase 
protein array analysis. The signal obtained was amplified using a Dako Cytomation–catalyzed system 
(Dako) and visualized by DAB colorimetric reaction. The slides were scanned, analyzed, and quantified 
using Microvigene software (VigeneTech Inc.) to generate spot intensity.  
Each dilution curve was fitted with a logistic model developed by the Department of Bioinformatics and 
Computational Biology (MD Anderson Cancer Center). The fitted curve is plotted with the signal 
intensities – both observed and fitted - on the y-axis and the log2-concentration of proteins on the x-axis 
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for diagnostic purposes. The protein concentrations of each set of slides were normalized by median 
polish, which was corrected across samples by the linear expression values using the median expression 
levels of all antibody experiments to calculate a loading correction factor for each sample. 
In vivo xenograft tumor models  
CD-1 nude mice (Charles River Laboratories, Wilmington, MA) at 7-12 weeks of age were maintained in a 
pathogen-free environment and all in vivo procedures were approved by the Synta Pharmaceuticals Corp. 
Institutional Animal Care and Use Committee. RT112 cells (5x10
6
) were subcutaneously implanted into 
female mice and animals bearing established tumors (~150 mm
3
) were randomized into treatment groups 
of 8. Mice were i.v. dosed with ganetespib (150 mg/kg) once weekly or p.o. dosed with BGJ398 (10 
mg/kg) daily, either alone or in combination, for 3 weeks. Tumor growth inhibition was monitored by tumor 
volume measurements twice weekly. As a measurement of in vivo efficacy, the %T/C value was 
determined from the change in average tumor volumes of each treated group relative to the vehicle-
treated animals. Statistical significance was determined using two-way ANOVA followed by Bonferroni 
post tests. 
Pharmacodynamics 
Nude mice bearing established RT112 xenografts were randomized into groups of 3 and administered a 
single bolus injection of ganetespib (150 mg/kg) or vehicle. At 24 and 72 hours post treatment, tumors 
were resected and homogenized in lysis buffer. Expression changes in cell signaling pathway 
components were interrogated using Pathscan RTK Signaling and Pathscan Intracellular Signaling Array 
Kits (Cell Signaling Technology) according to manufacturer protocols. Fluorescence readouts were 
measured using an Odyssey system (LI-COR) and average changes in signaling protein expression were 
calculated for each cohort. 
Bioanalysis  
In the first set of experiments, RT112 and SW780 cells were treated with graded concentrations of 
ganetespib or 17-DMAG (10-1000 nM) for 1 and 24 hours. Cell lysates were prepared for measurement 
of intracellular concentrations of the respective HSP90 inhibitors. RT112 and SW780 cells were also 
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treated with 1 µM ganetespib for 15 minutes, 1, 4, 8 and 24 hours. At each time point cell lysates were 
prepared and media was collected for analysis of intracellular and secreted concentrations of ganetespib 
and its glucuronidated metabolites. Bioanalysis was performed on equal protein concentrations from cell 
lysates or equal volumes of media. All samples were ultimately extracted by protein precipitation and 
analyzed by LC-MS/MS using an Agilent 1100 HPLC interfaced to an API 4000 tandem mass 
spectrometer (Applied Biosystems). A Phenomenex Kinetex 2.6µm C18 (30 x 2.1 mm) column was used 
with a run time of 3.5 min per sample. 
UGT1A gene expression analysis 
Total RNA was extracted from untreated SW780 and RT112 cells using the RNeasy Kit (Qiagen Inc.).  
cDNA (1 ȝg) was synthesized using an iScript cDNA synthesis kit (Bio-Rad). RT-PCR was performed 
using custom primers for UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, 
and UGT1A10 (Bio-Rad). The cycling conditions were 95
o
 C for 2 minutes, followed by 40 cycles of 95
o
 
for 10 seconds and 60
o
 for 30 seconds. Data were normalized to two housekeeping genes (hypoxanthine 
phosphoribosyltransferase 1 [HPRT1] and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) and 
analyzed by comparing 2íǻCt of the normalized sample. PCR was performed on a Bio-Rad iCycler iQ5 
(Bio-Rad). 
siRNA knockdown assay 
The Nucleofector® transfection system (Lonza) was used for cell transfections using standard 
manufacturer protocols. Briefly, for each siRNA construct 3-5 x10
5
 SW780 cells resuspended in 100 ȝl  
supplemented nucleofector solution were transiently transfected with siRNA-negative control or 300 nM 
siRNA-UGT1A7,8,9,10 mix (30 pmol/sample, Invitrogen). Transfected cells were grown for 72 hours. Cell 
cultures were then exposed to graded concentrations of ganetespib (0, 100, 1000 nM) for 24 hours prior 
to lysis and analysis by Western blot.  
Competitive UGT1A9 inhibitor assay 
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SW780 cells were cultured with 0.5 µM ganetespib, 100 µM and 300 µM propofol, both alone and in 
combination, or vehicle (DMSO) for 24 hours. At the end of the incubation, cells were harvested, lysed 
and protein expression changes evaluated by Western blot.  
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Results 
Ganetespib displays potent cytotoxic activity in FGFR3-driven bladder cancer lines 
Sensitivity to targeted HSP90 inhibition by ganetespib was evaluated using a panel of 20 bladder cancer 
cell lines of diverse genetic FGFR3 backgrounds (Table 1). In the majority of lines examined ganetespib 
reduced cellular viability with low nanomolar potency, including all that expressed activating point 
mutations. Further, ganetespib treatment could overcome an intrinsic FGFR inhibitor-resistant phenotype 
displayed by mutant FGFR3-expressing 97-7 and MGH-U3 cells (Supplementary Fig. S1). These lines 
harbor FGFR3
S249C
 and FGFR3
Y375C
 mutations, respectively, and were insensitive to the pan-FGFR 
inhibitor BGJ398 yet both remained susceptible to the cytotoxic effects of ganetespib exposure 
(Supplementary Fig. S1).   
Suppression of multiple oncogenic signaling cascades in FGFR3 fusion-driven RT112 bladder 
cancer cells by ganetespib 
From the initial analysis, RT112 cells were found to be acutely sensitive to ganetespib treatment (IC50 
value 9 nM, Table 1). Long considered over-expressers of wild type FGFR3, the recent identification of 
the FGFR3-TACC3 fusion gene product in these cells accounts for their critical dependence on FGFR3 
activity for growth and survival (9). Moreover, bladder cell lines now known to be FGFR3 fusion-positive, 
including RT112, have been reported to be highly sensitive to BGJ398 (20). In this regard, ganetespib 
was equipotent to selective FGFR inhibition in reducing cell viability in this line (Fig. 1A). This loss of 
viability was concurrent with activation of apoptosis as shown in Fig. 1B. RT112 cells were exposed to 
increasing concentrations of ganetespib and viability measured at 72 hours. This profile was compared to 
apoptotic induction determined by activated caspase 3/7 levels assessed 24 hours post treatment, which 
showed that ganetespib-induced cytotoxicity was mediated by an irreversible commitment to apoptosis. 
Next we examined molecular changes in client and signaling protein pathways associated with FGFR3-
TACC3 in ganetespib-treated RT112 cells (Fig. 1C). Ganetespib induced a robust and dose-dependent 
destabilization of FGFR3-TACC3 expression, in terms of both total and phosphorylated protein levels, 
suggesting that the FGFR3 fusion protein was highly responsive to HSP90 inhibition. Importantly, 
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targeted degradation of this oncogenic driver was accompanied by loss of downstream signaling effector 
activity (as evidenced by loss of phosphorylated ERK and AKT levels) and induction of BIM, an additional 
marker of apoptosis (Fig. 1C). Consistent with its alternative mode of action as a specific tyrosine kinase 
inhibitor, an effective dose of BGJ398 (100 nM) did not affect total FGFR3-TACC3 expression but 
resulted in a similar abrogation of autophosphorylated FGFR3-TACC3 activity, disruption of oncogenic 
pathways, and induction of apoptosis. When the kinetics of client protein loss in response to HSP90 
inhibition were examined (Fig. 1D), it was found that destabilization of the FGFR3-TACC3 fusion and the 
congruent alterations in downstream signaling were relatively rapid, occurring within 4 hours of 
ganetespib exposure. Indeed, the destabilization profile for the FGFR3-TACC3 protein was similar to that 
of HER2, a highly sensitive HSP90 client. 
A feature of targeted HSP90 blockade is the simultaneous disruption of multiple cellular signaling 
cascades and processes that are exquisitely dependent on the chaperoning function of the molecule. 
Therefore we performed a more extensive reverse phase protein array analysis of ganetespib effects in 
RT112 cells. In addition to the expected downregulation of client receptor tyrosine kinases such as HER2, 
MET and EGFR, ganetespib treatment also selectively altered the expression of a number of proteins 
involved in mitogen-activated protein kinase (MAPK), AKT, and mammalian target of rapamycin (mTOR) 
signaling and cell cycle regulation, along with predicted increases in the apoptotic markers caspase 7 and 
BIM (Table 2). Thus, the potent and selective disruption of FGFR3-mediated signaling coupled with 
coordinate effects on additional mitogenic and survival pathways in RT112 cells accounts for the potent 
cytotoxic activity of ganetespib in this line. 
Ganetespib in combination with FGFR3 tyrosine kinase inhibition confers superior antitumor 
activity in vitro and in vivo  
Based on their distinct mechanisms of action on FGFR3-TACC inhibition, we examined whether 
combining ganetespib and BGJ398 would lead to increased activity in FGFR3 fusion-dependent bladder 
cancer cells. To do this, we first evaluated the effects on cellular viability following combination exposure 
in the RT112 cell line (Fig. 2A). The bladder cancer cells were treated with increasing concentrations of 
ganetespib and/or BGJ398 and viability assessed after 72 hours. The percentages represent the degree 
P a g e  | 13 
 
of cell death at each individual dose level, which revealed that combinatorial benefit was achieved at all 
concentrations tested. For example, at the approximate IC50 concentrations for each inhibitor (9.6 nM for 
ganetespib and 5 nM for BGJ398), combined exposure resulted in 71% cell killing. Overall, all 
combinations of ganetespib and BGJ398 showed improved cell killing activity over single-agent treatment 
alone.  
To determine whether these effects on cell viability in vitro would translate to improved efficacy in vivo, 
RT112 xenograft bearing mice were treated with ganetespib and BGJ398, both as single agents and in 
combination. We have previously determined that the maximally tolerated dose of ganetespib on a weekly 
dosing regimen is 150 mg/kg (17). Weekly administration of ganetespib at this dosing level was 
comparable to daily dosing of BGJ398 at 10 mg/kg, with each compound inducing a similar degree of 
tumor regression (T/C values of -23% and -20%, respectively; Fig. 2B). Concurrent treatment with both 
drugs resulted in a significant enhancement of antitumor activity, causing 66% tumor regression. In 
addition, combination treatment was well tolerated, with no significant changes in body weights seen after 
3 weeks of treatment (data not shown). Thus, ganetespib and BGJ398, when combined, displayed 
superior antitumor efficacy compared to monotherapy in RT112 bladder tumor xenografts. 
Next pharmacodynamic analysis was performed in additional mice bearing RT112 xenografts to confirm 
that the ganetespib-induced tumor response correlated with target modulation in vivo. Animals were 
treated with a bolus injection of ganetespib at 150 mg/kg and tumors harvested 24 and 72 hours later. 
Control group mice were administered a single injection of vehicle and tumors excised at the same time 
points. Expression changes in components of multiple signaling pathways, including receptor tyrosine 
kinases and their effector proteins, were investigated using multiplexed antibody arrays; average changes 
for each treatment cohort are presented in Fig. 2C. Ganetespib exposure resulted in the deactivation of 
endogenous FGFR3-TACC3 activity, as evidenced by the significant repression of p-FGFR3 levels and 
congruent repression of phosphorylated ERK and AKT by 24 hours. These effects were sustained over 
time with recovery occurring at 72 hours post treatment. Similar kinetics were observed for signaling 
intermediates of the mTOR pathway (phosphorylated S6 ribosomal protein and PRAS40), consistent with 
what was observed following targeted HSP90 inhibition in vitro (Table 2). Overall, these data show that 
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single-dose ganetespib exerts a potent and rapid destabilizing effect on the FGFR3-TACC3 fusion kinase 
and its effectors in RT112 xenografts. 
Differential sensitivity of FGFR3 fusion-positive bladder cancer lines to HSP90 inhibitors 
As part of a previous study it was shown that RT112 and RT4 bladder cancer cells, which also express 
the FGFR3-TACC3 fusion protein, were sensitive to targeted HSP90 inhibition by the first-generation 
ansamycin compound 17-AAG (17-allylamino-17-demethoxygeldanamycin) (21). However, RT4 cells 
were largely insensitive to ganetespib exposure (Table 1). To explore this lack of activity with ganetespib 
we evaluated the cytotoxicity of four HSP90 inhibitors (HSP90i) in RT4 and SW780 cells: 17-AAG, the 
closely related ansamycin analog 17-DMAG (17-dimethylaminoethylamino-17- demethoxygeldanamycin), 
ganetespib, and another resorcinol-based second-generation inhibitor AUY922 (Fig. 3A). In RT4 cells, 
exposure to an ansamycin-based HSP90i resulted in dose-dependent cytotoxicity and low nanomolar IC50 
values. In contrast, ganetespib and AUY922 were minimally effective at reducing cellular viability with IC50 
values greater than 1 µM (Fig. 3A). 
At the molecular level, 17-DMAG and 17-AAG both effectively destabilized FGFR3 and higher weight 
FGFR3-TACC3 fusion protein expression in RT4 cells (Fig. 3B). This was accompanied by a concomitant 
loss of downstream ERK activity (Fig. 3C). In addition, two other sensitive HSP90 client proteins, HER2 
and CDC2, were similarly degraded in a concentration-dependent manner. Consistent with the viability 
results, a corresponding dose-dependent increase in BIM expression was observed supporting the 
premise that both of these first-generation HSP90i induced apoptosis in RT4 cells (Fig. 3C). As predicted 
by the sensitivity profile of this line, ganetespib had negligible effects on the expression of any of the 
same molecular markers (Fig. 3D). 
This pattern was repeated in the SW780 line which harbors an FGFR3-BAI1AP2L1 gene rearrangement. 
The two resorcinol-based inhibitors were again only weakly cytotoxic yet the cells remained acutely 
sensitive to 17-AAG and 17-DMAG treatment (Fig. 4A). In stark contrast to 17-AAG, neither ganetespib 
nor AUY922 were found to significantly affect FGFR3-BAI1AP2L1 fusion protein levels, wild-type FGFR3, 
downstream effector pathways (p-ERK, p-AKT), or other established HSP90 client proteins (MET, HER2) 
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(Fig. 4B). These data were additionally supported by the dose-dependent analysis of ganetespib activity 
shown in Fig. 4C. No changes in FGFR3-BAI1AP2L1, phosphorylated FGFR3, ERK, AKT or MEK, or 
MET levels were observed, suggesting that the HSP90 inhibitory activity of the compound was 
compromised in this cell line. Taken together, these data show that the FGFR3-TACC3 and FGFR3-
BAI1AP2L1 gene fusion products were sensitive HSP90 client proteins, as evidenced by the potent 
effects of 17-AAG and 17-DMAG on protein destabilization and cell viability in RT4 and SW780 cells, 
respectively.  However, the lack of client protein modulation and cytotoxic activity seen with ganetespib 
and AUY922 suggested that these two cell lines exhibited an intrinsic level of resistance to the resorcinol-
based, second-generation HSP90i. 
High expression of UGT1A enzyme expression in FGFR3 fusion-positive bladder cells results in 
glucuronidation and efflux of ganetespib  
To dissect the mechanisms underlying the differential sensitivities to specific HSP90i exhibited by the 
FGFR3 fusion-positive cell lines, we first compared the intracellular concentrations of ganetespib and 17-
DMAG in the ‘resorcinol-sensitive’ RT112 and ‘resorcinol-resistant’ SW780 cell lines as a function of time 
(Fig. 4A). In RT112 cells, both compounds accumulated in a dose-dependent manner 1 hour post 
treatment, albeit with comparatively higher total ganetespib levels than 17-DMAG at each concentration 
tested. Moreover, the intracellular levels for each HSP90i seen after 1 hour appeared to approach 
saturation since no significant increases were observed at the 24-hour time point (Fig. 5A, left panel). In 
the SW780 cell line, the initial accumulations of ganetespib and 17-DMAG were indistinguishable, with 
each HSP90i readily entering and accumulating to near identical concentrations at 1 hour. By 24 hours, 
levels of 17-DMAG were maintained and modestly increased; in stark contrast virtually no ganetespib was 
detectable within the intracellular compartment of SW780 (Fig. 5A, right panel). 
These data suggested that ganetespib resistance was not due to differences in HSP90 biology but likely 
attributable to drug efflux and/or metabolism mechanisms. Similar to AUY922 (22), ganetespib is 
susceptible to metabolism by the UGT1A family of UDP-glucuronosyltransferase enzymes that transform 
small lipophilic molecules into water-soluble, excretable metabolites (23). Therefore the intracellular and 
secreted levels of ganetespib and its glucuronidated metabolites were measured in RT112 and SW780 
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cells as a function of time (Fig. 5B). No glucuronidated form of ganetespib was detectable within RT112 
cells over a 24-hour time course and only a minor concentration of metabolites was observed in the 
culture medium at the last time point (Fig. 5B, left panel). Notably, approximately 40% of the total 
intracellular drug levels present in the SW780 line 15 minutes following drug addition were glucuronidated 
compounds (Fig. 5B, right panel), indicating that ganetespib was being rapidly metabolized in these cells. 
In agreement with the data shown in Fig. 5A, intracellular SW780 ganetespib concentrations decreased to 
undetectable levels by 24 hours; this was concomitant with a marked accumulation of metabolite 
secretion into the culture media with time (Fig. 5B, right panel).  
When overall UGT1A protein expression was evaluated in the three FGFR3 fusion-positive bladder lines 
it was found that both SW780 and RT4 cells expressed considerably higher endogenous enzyme levels 
compared to RT112 (Fig. 5C). Further, UGT1A protein expression was virtually undetectable in 97-7 
bladder cancer cells, which were also sensitive to ganetespib exposure (Supplementary Fig. S1). We 
subsequently performed a comparative PCR analysis assessing relative mRNA levels of individual 
UGT1A family enzymes to examine differences in metabolism-related gene expression between the 
RT112 and SW780 cell lines (Fig. 5D). From this screen it was found that SW780 cells showed 
significantly higher basal UGT1A family expression compared to the RT112 line, most notably the 
UGT1A7, UGT1A8, UGT1A9, and UGT1A10 isoforms – which represent a cluster of genes encoding 
highly homologous enzymes within the UGT1A subfamily (24). Of note, we have previously identified 
UGT1A9 as the primary UGT enzyme responsible for ganetespib glucuronidation in liver microsome 
assays (data not shown). To confirm the PCR findings, UGT1A9 and 1A10 protein expression were 
individually evaluated in the panel of lines, with UGT1A9- and UGT1A10-tranfected 293T cells serving as 
a positive control (Fig. 5E). As predicted, the SW780 and RT4 cell lines expressed considerably higher 
endogenous levels of both enzymes compared to RT112 cells. These data indicated that of the three 
FGFR3 fusion-positive lines, SW780 and RT4 cells had a higher intrinsic propensity to metabolize 
ganetespib than RT112, and suggested that this phenotypic variation contributed to the differential 
sensitivities seen following drug exposure. Taken together, our findings support the premise that high 
endogenous UGT1A enzyme expression in SW780 cells promoted the rapid glucuronidation and 
subsequent efflux of ganetespib, sufficient to account for its lack of bioactivity in this line. 
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Targeted reductions in UGT1A activity by RNA interference or competitive inhibition sensitize 
SW780 bladder cells to ganetespib  
To confirm this putative mechanism of action, we performed a series of reversion experiments in SW780 
bladder cells. In the first, UGT expression was modulated by transfecting SW780 cells with a non-target 
(control) or UGT1A7,8,9,10-targeting siRNA probe for 72 hours. HSP90 inhibitory activity was then 
compared in control and UGT1A-deficient SW780 cells exposed to increasing concentrations of 
ganetespib for a further 24 hour period (Fig. 6A). Immunoblotting revealed that targeted RNA interference 
effectively resulted in the complete abrogation of UGT1A9 and UGT1A10 protein expression. 
Upregulation of heat shock protein 70 (HSP70) was used as a surrogate marker of HSP90 inhibition (25) 
and effects on two well-established client proteins, epidermal growth factor receptor (EGFR) and cyclin-
dependent kinase 1 (CDK1), were assayed. Control cells were largely insensitive to the effects of 
ganetespib exposure, reflecting the phenotype of the parental SW780 line. In stark contrast, 
UGT1A9/1A10-deficient SW780 cells showed marked increases in HSP70 expression, alongside dose-
dependent destabilization of both EGFR and CDK1. Moreover, ganetespib treatment at the highest dose 
resulted in the induction of apoptosis, as evidenced by cleaved PARP expression. Taken together, these 
data showed that siRNA knockdown of UGT1A9 and 1A10 expression could overcome intrinsic 
ganetespib resistance in SW780 bladder cells. 
Reductions in glucuronidation activity were also assessed by treating SW780 cells with ganetespib in the 
presence or absence of propofol, a competitive inhibitor of UGT1A9 activity (26). As expected, ganetespib 
treatment alone had only minor effects on HSP70 induction and client protein stability; propofol exposure 
(100 and 300 µM concentrations) exhibited no discernable effects on HSP90 activity (Fig. 6B). However, 
in the presence of propofol, SW780 cells were sensitized to ganetespib treatment as shown by robust 
HSP70 upregulation, more complete degradation of both client proteins, and marked elevations in 
cleaved PARP levels. Together with the siRNA data, these observations provide further support for 
glucuronidation-based metabolism as representing the primary mechanism of ganetespib resistance in 
this bladder model. 
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Finally, we reasoned that the differences in metabolic profiles exhibited by the FGFR3-fusion positive 
bladder cancer lines may also confer differential sensitivity to a wider variety of therapeutic agents, in 
addition to HSP90i. To examine this possibility, we interrogated the Genomics of Drug Sensitivity in 
Cancer Project database (http://www.cancerrxgene.org). Clinically validated, targeted compounds that 
showed 3-fold or higher changes in IC50 cytotoxicity values for SW780 cells compared to the RT112 line 
are listed in Supplementary Table S1. In agreement with the findings shown in Fig. 4A, NVP-AUY922 was 
identified in the screen, as was another resorcinol-based HSP90i CCT018159. In general terms, targeted 
agents that exhibited the highest potential for Phase II/glucuronidation metabolism were associated with 
higher IC50 ratios, indicating that SW780 cells were far less sensitive to drug treatment than RT112. 
Overall, these data suggest that metabolism-based resistance linked to UGT1A expression may 
represent a more general consideration for the evaluation of variety of anticancer compounds in bladder 
tumors.   
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Discussion 
FGFR3 has long been considered an attractive therapeutic target in bladder cancer based on its high 
frequency of dysregulated activity, particularly through mutation and/or over-expression (11). Importantly, 
FGFR3 has been implicated to play a key oncogenic role in both non-invasive and invasive disease (7). 
The recent discovery of genomic FGFR3 rearrangements in a subset of bladder tumors provides another 
pathogenic mechanism for aberrant FGFR3 activation in this disease and one with particular relevance 
for the identification of patients who may ultimately benefit from targeted FGFR inhibition (9). The fusion 
gene products generated by rearrangements of FGFR3 with either TACC3 or BAI1AP2L1 are tumorigenic 
and create dependency in cell lines harboring such alterations (9, 10). Moreover, transforming fusions of 
FGFR and TACC genes have also been found in glioblastoma (27), suggesting that translocation may 
represent a more universal mechanism of FGFR dysregulation that is conserved across tumor types. Of 
note, constitutively active fusion gene products are well characterized as critical driver proteins in other 
cancer types, such as EML4-ALK in non-small cell lung cancer and BCR-ABL in chronic myeloid leukemia 
(28-30). Indeed, the clinical successes of agents directed against such proteins (e.g., crizotinib for EML4-
ALK and imatinib for BCR-ABL) have served as paradigms for the design and application of molecularly 
targeted therapy in cancer. A number of small molecules with activity against FGFRs are currently under 
development, the majority of which are multi-kinase inhibitors originally designed as antiangiogenic 
agents against other growth factor receptors (31). Recently, more selective and potent pan-FGFR 
inhibitors, including BGJ398 (20), have entered early stage clinical evaluation in bladder and other tumor 
types (31). 
In this report we show that bladder cancer cell lines harboring FGFR3-TACC3 and FGFR3-BAI1AP2L1 
gene rearrangements are sensitive to HSP90 inhibition. Previously, 17-AAG has been reported to exert in 
vitro cytotoxic activity in RT112 and RT4 cells (21), however the presence and significance of the FGFR3-
TACC3 product expressed in these lines were not recognized in that study. Here we provide the first 
demonstration that FGFR3 fusion proteins expressed by bladder cancer cells are reliant on the 
chaperoning activity of the HSP90 molecule for their stability and function, as evidenced by their 
pronounced destabilization following HSP90i treatment (in an inhibitor-dependent context), ultimately 
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leading to loss of tumor cell viability. While this finding alone does not unequivocally identify FGFR3 
fusions as direct HSP90 substrates, it is important to note that the FGFR3 kinase itself is a bona fide 
HSP90 client protein (32, 33). Indeed, within the FGFR family of receptor tyrosine kinases there is a 
hierarchical degree of destabilization induced by selective HSP90 inhibitors, with FGFR3 representing the 
member most sensitive to chaperone inhibition (33).  In RT112 cells, ganetespib exposure resulted in the 
rapid and potent degradation of FGFR3-TACC3 protein expression, loss of downstream effector 
signaling, and subsequent induction of apoptosis. HSP90 blockade was as effective as direct kinase 
inhibition afforded by BGJ398 treatment and, importantly, the in vitro antitumor activity of both compounds 
was recapitulated in vivo. BGJ398 administration induced tumor regressions in FGFR3-TACC3-driven 
RT112 xenografts - a response that was both consistent with, and superior to, what has been observed 
with the small molecule FGFR kinase inhibitor PD173074 in RT4 and SW780 models (10). A weekly 
dosing schedule of ganetespib was equally efficacious as the BGJ398 regimen. We extended these 
findings by combining the two modalities of HSP90 inhibition and selective FGFR3 targeting in RT112 
tumors, which resulted in improved efficacy over that achieved with either agent alone. Together with the 
broader spectrum of biological activity conferred by ganetespib exposure, these data strongly suggest 
that HSP90 inhibition offers an alternative, and potentially complementary, strategy to selective kinase 
inhibition in FGFR3 fusion-driven bladder cancer.  
An interesting feature of FGFR fusion-positive tumor lines is their enhanced susceptibility to 
pharmacologic inhibition by selective FGFR kinase inhibitors over activating point mutations (10). In this 
regard, ganetespib retained full potency against two BGJ398-resistant bladder cell lines, 97-7 and MGH-
U3, which bear mutant FGFR3
S249C
 and FGFR3
Y375C
 receptors, respectively. Further, ganetespib was also 
highly potent in reducing cell viability in a number of bladder cell lines with wild type FGFR3 status – 
highlighting the therapeutic potential of pharmacological HSP90 blockade for affecting this validated and 
actionable disease target. Clinically, the field of FGFR-targeted therapy is still in its infancy and the 
translational benefit of any specific agent is yet to be realized. However a recurring theme in the clinical 
experience with many targeted kinase inhibitor drugs, including imatinib and crizotinib, is that their long-
term efficacy is often hampered by the invariable development of acquired resistance, commonly arising 
due to the acquisition of secondary mutations in their respective kinase targets (34, 35). We and others 
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have previously shown that HSP90 inhibition is an effective approach for overcoming oncogenic EML4-
ALK activity in non-small cell lung cancer (18, 36, 37). Significantly, ganetespib also displayed potent 
activity against a variety of acquired ALK mutations that confer crizotinib resistance in multiple 
experimental models and in the clinical setting (18). In light of the broader activity profile of ganetespib in 
affecting both activating mutations and translocations of FGFR3, it is reasonable to suggest that HSP90 
blockade may warrant further investigation as a means to overcome acquired resistance should similar 
mechanisms arise that allow escape from targeted FGFR agents. 
A significant finding of this study was the differential sensitivities exhibited by the fusion-positive bladder 
lines to alternate classes of HSP90 inhibitors. In particular, cell fate following HSP90i exposure in RT4 
and SW780 cells varied according to the chemical class of inhibitor used. Both of the first-generation 
ansamycin inhibitors 17-AAG and 17-DMAG potently induced cell death, and loss of viability was 
associated with destabilization of the individual FGFR3 fusions expressed by each line. However, and in 
contrast to RT112 cells, both lines were largely resistant to ganetespib treatment or exposure to AUY922, 
a second resorcinol-based HSP90i. Mechanistically, the rapid metabolism (via glucuronidation) and 
subsequent efflux of ganetespib from SW780 cells was sufficient to account for the lack of HSP90 
inhibitory activity. This was validated by inhibiting the high endogenous levels of UGT1A9 and UGT1A10 
expression in SW780 by RNA interference, as well as competitive inhibition of the UGT1A9 isoform by 
propofol. Both experimental strategies overcame the intrinsically resistant phenotype of this bladder line, 
and conferred sensitivity to ganetespib exposure. This is the first demonstration of ganetespib metabolism 
as a contributing factor to drug resistance and thus has clear implications for the clinical application of the 
compound. Overall, response to the second-generation resorcinol inhibitors appeared intimately linked to 
the endogenous level of UGT1A family enzyme expression, the primary catalysts of glucuronidation 
reactions in multiple human tissues (23). Interestingly, the UGT1A gene cluster has been identified as a 
novel susceptibility locus for bladder cancer using genome-wide association studies (38). Further, 
experimental evidence has shown that UGT1A expression becomes down-regulated during bladder 
cancer progression in animal models (39), consistent with the hypothesis that UGT variants mapping to 
this region may provide a protective, tumor-suppressive function in bladder cells (40). FGFR3 fusion 
protein expression is likely to be an important biomarker to aid in patient selection when evaluating novel 
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bladder cancer treatments, due to an increased susceptibility of fusion-bearing tumor cells to targeted 
FGFR therapies (9). Based on the findings presented here, UGT1A expression in bladder tumors may 
represent an additional marker with direct translational relevance for the clinical evaluation of HSP90 
inhibitor-based strategies. Moreover, we have observed high levels of UGT1A in subsets of lung cancer 
patients (D. Proia, unpublished observations). Combining these results with patient responses in ongoing 
clinical trials of ganetespib may be informative as to the potential use of UGT1A as a predictive biomarker 
for future studies. 
In summary, this study provides preclinical proof of concept that targeting FGFR3 gene fusions via 
selective HSP90 inhibition represents a rational therapeutic strategy for bladder tumors oncogenically 
driven by this mechanism of aberrant receptor activation. Based on select advantages of this approach 
over FGFR-specific kinase inhibitors, these findings are likely to provide a framework for the development 
of new targeted agents and biomarkers designed to improve therapeutic outcomes for bladder cancer 
patients. 
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Table 1. In vitro cytotoxicity values of ganetespib in bladder cancer cell lines. 
 
Cell line 
 
Ganetespib IC50 
(nM) 
 
 
FGFR3 status 
   
DSH1 6 WT 
SW-1710 6 WT 
T24 7 WT 
RT112 9 FGFR3-TACC3 
639-V 10 R248C 
SCaBER 10 WT 
BFTC 17 WT 
J82 18 K652E 
HT-1376 21 WT 
647-V 27 WT 
UM-UC3 33 WT 
LB831-BLC 34 WT 
KU-19-19 36 WT 
97-7 38 S249C 
5637 44 WT 
HT-1197 53 WT 
MGH-U3 53 Y375C 
TCCSUP 142 WT 
RT4 1733 FGFR3-TACC3 
SW780 3451 FGFR3-BAIAP2L1 
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Table 2. Fold-changes in protein expression following ganetespib treatment in RT112 bladder cancer 
cells using reverse phase protein array analysis. 
 
Cellular Target 
 
Protein 
 
Fold Change 
 MET (pY1235) -2.7 
 HER2 -2.2 
Receptor Tyrosine Kinases HER2 (pY1248) -2.2 
 EGFR (pY1068)  -1.9 
 HER3  -1.6 
 EGFR -1.5 
 AKT (pS473) -2.5 
 AKT -2.4 
AKT signaling GSK3-A/B (pS2/S9) -1.8 
 PDK1 (pS241) -1.7 
 GSK3-A/B  -1.5 
 PDK1  -1.4 
 C-RAF -1.8 
 MAPK (pT202/Y204) -1.5 
MAPK pathway MEK1 (pS217/S221) -1.4 
 Src (pY527) -1.4 
 P90RSK (pT359/S363) -1.4 
Transcription factors c-Myc -2.5 
 NF-κB p65 (pS536) -2.3 
 S6 (pS235/S236) -13.2 
 S6 (pS240/S244) -8.9 
 P70S6K (pT389) -4.7 
mTOR pathway 4E-BP1 (pS65) -2.5 
 mTOR (pS2448) -2.2 
 Tuberin -2.2 
 TSC1 -1.3 
 PRAS40 (pT246) -1.2 
 Rb (pS807/811) -4.6 
 Chk1 -3.2 
Cell cycle regulation Cyclin B1 -1.9 
 CDK1 -1.4 
 p21 +1.4 
 p27 +1.5 
Stress response HSP70/72 +3.0 
 HSP90 alpha +1.6 
Apoptosis Caspase 7 (cleaved D198) +2.5 
 BIM +1.4 
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Figure legends 
Figure 1. Cellular viability, apoptosis induction and pathway modulation in FGFR3-TACC3-expressing 
RT112 cells following ganetespib treatment. A, RT112 cells were treated with increasing concentrations 
of ganetespib or BGJ398 and viability assessed after 72 hours. B, RT112 cells were treated with graded 
concentrations of ganetespib, as indicated. Caspase 3/7 activity was measured at 24 hours and viability 
assessed at 72 hours post-treatment. RLU, relative luminescence units. C,  RT112 cells were exposed to 
increasing concentrations of ganetespib, or BGJ398 at 100nM, for 24 hours. The expression levels of 
FGFR3-TACC3, phosphorylated FGFR3, ERK and AKT (p-FGFR, p-ERK, p-AKT) and BIM were 
determined by immunoblotting. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. D, RT112 cells 
were treated with 200 nM ganetespib and harvested at 2, 4, 6 and 24 hours. Lysates were immunoblotted 
with the indicated antibodies. V, vehicle control at 24 hour time point. 
Figure 2. Enhanced activity of ganetespib in combination with the pan-FGFR TKI inhibitor BGJ398 in vitro 
and in vivo. A, 72-hour combination viability assay with ganetespib and BGJ398 in RT112 cells. 
Percentages represent the amount of cell death observed at each of the corresponding dose levels. B, 
Mice bearing established RT112 xenografts (n=8 mice/group) were i.v. dosed with ganetespib (150 
mg/kg) once weekly and BGJ398 (10 mg/kg) administered p.o. 7x/week, either alone or in combination. 
Percent T/C values are indicated to the right of each growth curve and the error bars are the SEM. * p= 
0.0005. C, Mice bearing established RT112 xenografts (n=3 animals/group) were treated with either 
vehicle or ganetespib (150 mg/kg) for 24 and 72 hours. Tumors were resected and the relative expression 
levels of the indicated signaling proteins determined by phosphoprotein array analysis. 
Figure 3.  Differential sensitivity of RT4 bladder cancer cells to ansamycin- and resorcinol-based HSP90 
inhibitors. A, RT4 cells were treated with increasing concentrations of ganetespib, AUY922, 17-AAG and 
17-DMAG. Cell viability was assessed at 72 hours. B, RT4 cells were exposed to graded concentrations 
of 17-AAG or 17-DMAG, as indicated. The expression levels of wild type FGFR3 and the FGFR3-TACC3 
fusion protein (higher MW bands) were determined by immunoblotting. V, vehicle control. C, RT4 cells 
were treated with 17-DMAG or 17-AAG, as indicated, for 24 hours. The levels of p-ERK, HER2, CDC2 
and BIM were determined by immunoblotting. D, RT4 cells were exposed to graded concentrations of 
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ganetespib (0.1-1 µM) for 24 hours and lysates immunoblotted with the indicated antibodies. V, vehicle 
control. 
Figure 4. Differential sensitivity of SW780 bladder cancer cells to ansamycin- and resorcinol-based 
HSP90 inhibitors. A, SW780 cells were treated with increasing concentrations of ganetespib, AUY922, 
17-AAG and 17-DMAG. Cell viability was assessed at 72 hours. B, SW780 cells were treated with 
ganetespib (gpib), AUY922 or 17-AAG at the indicated concentrations for 24 hours. Lysates were 
immunoblotted with the indicated antibodies. V, vehicle control. C, SW780 cells were exposed to graded 
concentrations of ganetespib (0.1-5 µM) for 24 hours and lysates immunoblotted with the indicated 
antibodies. 
Figure 5.  High endogenous UGT1A enzyme expression in bladder cancer cells promotes the rapid 
metabolism of ganetespib. A, RT112 and SW780 cells were treated with graded concentrations of 
ganetespib or 17-DMAG (10-1000 nM) for 1 and 24 hours, as indicated. Intracellular drug concentrations 
of the respective HSP90 inhibitors are plotted as a function of dose and time. B, RT112 and SW780 cells 
were cultured in 1 µM ganetespib.  Cellular lysates were prepared and culture media collected at 15 
minutes, 1, 4, 8, and 24 hours. The total intracellular concentration of ganetespib and its glucuronidated 
metabolites (glu-ganetespib), as well as drug concentrations in the media, were determined by LC-
MS/MS. C, Cellular lysates prepared from SW780, RT4, RT112 and 97-7 bladder cancer cell lines were 
immunoblotted for UGT1A enzyme expression. D, Scatter plot of differential UGT1A gene expression 
between the SW780 and RT112 cell lines following PCR analysis. The axes of the scatter plot are the 
relative mRNA expression levels; outer parallel lines indicate a fourfold-change in gene expression 
threshold. Each spot represents an individual UGT1A gene family member, as indicated. E, Cellular 
lysates prepared from UGT1A10- and 1A9-transfected 293T cells (positive controls), SW780, RT4, and 
RT112 bladder cancer cell lines were immunoblotted for UGT1A9 and UGT1A10 enzyme expression. 
Figure 6. Inhibition of UGT1A activity by RNA interference or competitive inhibition overcomes 
ganetespib resistance in SW780 cells. A, SW780 cells were transfected with non-targeting control or 
UGT1A7,8,9,10 siRNA for 72 hours. Cultures were treated with graded concentrations of ganetespib as 
shown for 24 hours. Lysates were immunoblotted with the indicated antibodies. B, SW780 cells were 
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treated with vehicle, ganetespib (0.5 µM), or propofol (100 µM or 300 µM), either alone or in combination, 
for 24 hours. Lysates were immunoblotted with the indicated antibodies. 
 






